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Abstract
Background: Despite its first description over 40 years ago, knowledge of the clinical course of isovaleric acidemia
(IVA), a disorder predisposing to severe acidotic episodes during catabolic stress, is still anecdotal. We aimed to
investigate the phenotypic presentation and factors determining the neurological and neurocognitive outcomes of
patients diagnosed with IVA following clinical manifestation.
Methods: Retrospective data on 21 children and adults with symptomatic IVA diagnosed from 1976 to 1999 were
analyzed for outcome determinants including age at diagnosis and number of catabolic episodes. Sixteen of 21
patients were evaluated cross-sectionally focusing on the neurological and neurocognitive status. Additionally, 155
cases of patients with IVA published in the international literature were reviewed and analyzed for outcome
parameters including mortality.
Results: 57% of study patients (12/21) were diagnosed within the first weeks of life and 43% (9/21) in childhood.
An acute metabolic attack was the main cause of diagnostic work-up. 44% of investigated study patients (7/16)
showed mild motor dysfunction and only 19% (3/16) had cognitive deficits. No other organ complications were
found. The patients’ intelligence quotient was not related to the number of catabolic episodes but was inversely
related to age at diagnosis. In published cases, mortality was high (33%) if associated with neonatal diagnosis,
following manifestation at an average age of 7 days.
Conclusions: Within the group of “classical” organic acidurias, IVA appears to be exceptional considering its milder
neuropathologic implications. The potential to avoid neonatal mortality and to improve neurologic and cognitive
outcome under early treatment reinforces IVA to be qualified for newborn screening.
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Background
Isovaleric acidemia (IVA) is known as one of the “classi-
cal” organic acidemias/acidurias. It is caused by a genetic
deficiency of isovaleryl-CoA dehydrogenase (IVD) cata-
lyzing the third step in leucine catabolism. The enzyme
defect results in the accumulation of derivatives of isova-
leryl-CoA including free isovaleric acid, 3-hydroxyisova-
leric acid, isovaleryl (C5)-carnitine, and isovalerylglycine
(IVG) which partly may exert neurotoxicity.
The clinical presentation of IVA appears to be highly
variable ranging from severely affected to asymptomatic
subjects [1]. It may present either in the neonatal period
as an acute episode of fulminant metabolic acidosis
which may lead to coma and death ("acute neonatal
form”) or later as a “chronic intermittent form” asso-
ciated with developmental delay, with or without recur-
rent acidotic episodes during catabolic stress. Proposed
strategies for long-term treatment of IVA comprise pro-
tein or leucine restriction to reduce the production of
toxic metabolites from leucine degradation, and carni-
tine and/or glycine to enhance the conversion of poten-
tially neurotoxic free isovaleric acid into non-toxic
carnitine and glycine conjugates which are readily
excreted in the urine [2,3].
Recently, the identification of a novel mild and poten-
tially asymptomatic form of IVA and its association with
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reported [1]. This type of IVA is frequent in subjects
identified through newborn screening (NBS) and asso-
ciated with less pronounced metabolite elevations than
in clinically detected patients. This goes along with the
finding of a higher incidence of IVA in the NBS popula-
tion than in clinically detected cases [4].
Although the detection of various metabolic disor-
ders including IVA by NBS using tandem mass spec-
trometry is technically feasible [5], policies for the
inclusion of disorders in NBS programs world-wide are
diverse and remain a matter of debate. With respect to
IVA, there is an entire lack of larger-scale studies
investigating the long-term outcome in clinically diag-
nosed patients. A better understanding of the clinical
course of IVA is therefore required in order to allow
for 1) an evidence-based decision-making on the inclu-
sion of IVA in NBS programs and 2) a prospective
assessment of patient outcome in countries in which
IVA has already been incorporated into the NBS dis-
ease panel. This study provides data on the largest ser-
ies of patients with IVA reported to date highlighting
the clinical course of the disease and the neurological
and cognitive outcome.
Methods
Study design and patients
Twenty-one patients with IVA from 21 families living in
Germany were enrolled in a cross-sectional study (Table
1). All were diagnosed due to clinical presentation
between 1976 and 1999, prior to the inclusion of IVA as
a target disorder in German NBS programs. In all cases,
IVA was confirmed by demonstrating IVA-specific
metabolites in plasma and/or urine.
The study was conducted in two steps (Figure 1). In a
first step, clinical information was collected for each
patient by review of the patients’ medical records and
use of a questionnaire which was sent to the patients’
attending metabolic specialists, specifically addressing
the patients’ age at diagnosis, catabolic episodes (fre-
quency, severity, and triggers), clinical findings, sociode-
mographic status, psychomotor and cognitive
development as well as biochemical and treatment data.
For one patient the relevant information was obtained
only post mortem. Next, 20 patients were invited to take
part in the second step of the study comprising physical
examination, cognitive testing, and laboratory investiga-
tions. Sixteen patients agreed to participate. The partici-
pants were examined during a one-day study visit at the
University Children’sH o s p i t a li nF r e i b u r g ,G e r m a n y( n
= 12), or if this was impossible, at the pediatric meta-
bolic department in charge (n = 4), within a study per-
iod of 10 months. Informed consent was obtained from
the patients and/or patients’ parents. The study was
approved by the Institutional Review Board of the Uni-
versity Freiburg, Germany.
Systematic literature review
We performed a literature review by searching PubMed
using the terms “isovaleric acidemia”, “isovaleric acid-
uria”, “organic acidemia”,a n d“organic aciduria” in
order to obtain comprehensive information on the clini-
cal course of IVA from a larger number of patients. 155
cases of clinically diagnosed IVA published between Jan-
uary 1967 and June 2011 were identified and reviewed,
specifically focusing on the patients’ age of disease
onset, mortality, and neurocognitive outcome (Addi-
tional file 1, Table S1).
Definition of the terms “time of diagnosis” and “catabolic
episode”
The term “early diagnosis” refers to a diagnosis made
within the first 5 weeks of age, whereas the term “late
diagnosis” refers to a diagnosis made thereafter (Table
1). Patients with IVA are prone to recurrent episodes of
metabolic acidosis following catabolic stress e.g. during
intercurrent illness, but sometimes without any overt
cause. In between, they may be without pathological
findings. To estimate the impact of catabolic episodes
on the patients’ outcome, three degrees of episode
severity were defined. The term “severe catabolic epi-
sode” refers to an acute attack of metabolic acidosis
associated with apathy or coma and neurological signs
(e.g. seizures) requiring intensive supportive treatment.
“Moderate catabolic episode” refers to an acute attack of
illness with at least one clinical (e.g. recurrent emesis,
lethargy) and/or biochemical (e.g. metabolic acidosis)
sign not requiring intensive care treatment. “Impending
catabolic episode” is defined as acute illness not distin-
guishable from a common infection without metabolic
acidosis (Table 1).
Clinical examination
All step II participants underwent a careful physical and
neurological examination including anthropometric
assessments. Neurological examination comprised
assessment of gait and station, deep tendon reflexes,
motor coordination, gross motor function, and cranial
nerve function as well as, in patients older than 5 years,
diadochokinesis of the upper and lower limbs.
Evaluation of psychomotor development and cognitive
performance
In step II participants aged 1 to 3.8 years, psychomotor
development was evaluated using the Denver Develop-
mental Screening Test (DDST) (Table 2). To determine
the intelligence quotient (IQ) in older step II partici-
pants, the age-appropriate German versions of the
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years the Kaufman Assessment Battery for Children (K-
ABC) and in one case the Kramer IQ test (Kramer); in
the remaining adolescent and adult patients the Wechs-
ler Intelligence Scale for Children Version III (HAWIK-
III) and the Wechsler Adult Intelligence Scale-Revised
(HAWIE-R), respectively. In one step II participant with
severe retardation in whom testing was not possible and
four patients not participating in step II, information on
psychomotor development and/or IQ was obtained from
the questionnaire and medical records (Table 2).
Laboratory investigations
In all 16 step II participants, routine laboratory tests
including vitamins and minerals as well as plasma
amino acids were performed in order to screen for var-
ious organ involvements and potential nutritional defi-
cits, as they were on a protein-restricted diet (Table 1;
Additional file 2, Table S2). In addition, the following
disease-specific biochemical investigations were carried
out: quantification of the IVD activity in the patients’
Epstein-Barr virus-transformed lymphocytes using the
anaerobic electron-transfer flavoprotein reduction assay
[6], measurement of the C5-carnitine accumulation in
the patients’ lymphocyte culture medium as described
previously [1], and quantification of IVG excreted in
urine (Additional file 2, Table S2).
Statistical analysis
Statistical analyses were performed using SPSS 16.0 (2007,
IBM, Chicago, Illinois). For the determination of the corre-
lation of patients’ IQ scores with the number of catabolic
episodes, linear correlation analyses were performed using
the Kendall tau coefficient. Correlation of patients’ IQ
scores with age at diagnosis was determined using the
Pearson coefficient, and the relative impact of these
Table 1 Characteristics of study patients with symptomatic isovaleric acidemia.
ID Age at study (y) Sex Ethnicity Age at diagnosis Frequency of
catabolic
episodes
b
Medical long-term
treatment
c
Leucine-free amino acid supplementation
d
SE MO IM C C+G none
1 2.2 M DE 1 w 0 1 0 X -
2 3.8 M DE 1.6 y 0 1 1 X X
3 5.3 F TR 1 w 0 5 0 X -
4 6.1 F DE 3.7 y 0 2 2 X -
5 6.5 F DE 1 w 1 2 0 X X
6 7.1 F DE 1 w 1 5 3 X X
7 7.5 M DE 1 w 1 0 1 X -
8 8.4 M TR 6.3 y 1 1 2 X -
9 10.7 F TR 1 w 1 5 2 X X
10 10.9 F TR 1 w 2 8 3 X X
11
a 11.5 F GR 4.5 y 0 1 0 X -
12 11.6 M DE 2 w 1 2 0 X Until age 5 y
13 14.2 M DE 2.4 y 2 0 0 X -
14 15.4 M DE 5 w 0 2 2 X Until age 15 y
15
a 16.5 F TR 2.4 y 1 1 0 X -
16 19.0 F IT 1 w 1 5 0 X During infancy
17
a 20.0 M TR 5.3 y 0 5 0 X -
18
a 20.0 F TR 3.7 y 0 1 4 NA NA NA -
19 24.4 M DE 1 w 0 4 2 X During infancy
20 25.3 F GR 6.5 y 0 5 2 X -
21
a Deceased M DE 2 w 1 0 0 - - - -
Information on the clinical presentation including age at diagnosis, number of catabolic episodes, and treatment modalities is detailed.
C = L-carnitine, F = female, G = L-glycine, DE = German, GR = Greek, IT = Italian, ID = identification number, IM = impending catabolic episode, M = male, MO =
moderate catabolic episode, NA = not available, SE = severe catabolic episode, TR = Turkish, w = week(s), y = years
a Patient not participating in study step II; information was available from questionnaire and/or medical records only.
b Total number of catabolic episodes (as defined in the Methods section), both prior to and following the diagnosis.
c L-carnitine intake ranged from 10 to 144 mg/kg body weight per day (median 100 mg/kg × d); L-glycine was administered in doses between 53 and 200 mg/
kg body weight per day (median 112 mg/kg × d).
d All patients were on a protein-restricted diet.
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by linear regression analyses. The Mann-Whitney U test
was used to assess differences in age at initial manifesta-
tion between deceased and surviving patients within the
early diagnosis group of literature patients. P <0 . 0 5w a s
considered statistically significant.
Results
Study patients
Characteristics
The age of 20 living patients entering step I of the study
r a n g e df r o m2t o2 5y e a r s( m e d i a n1 1 . 2y e a r s ) .O n e
patient died at the age of 13 days (Table 1, patient ID
21). Sixteen (76%) patients were in the pediatric and
adolescent age group (< 18 years), five patients were in
the adult age group (19 to 25 years). The male to female
ratio was 0.9. Eleven patients were natives; the remain-
der were migrants of Turkish, Greek, and Italian origin.
The parental consanguinity rate was 48% (10/21) overall,
with a higher rate (80%, 8/10) in migrant families. Three
patients (14%, 3/21) had living siblings also affected with
IVA. In three families (14%, 3/21), unexplained death of
a preceding sibling had occurred within the first 3
months of life. In all 21 study patients, pregnancy, birth,
and early postnatal period were uneventful and birth
weight was within normal limits.
Biochemical phenotype
Both the IVD activity in the patients’ transformed lym-
phocytes measured below the detection limit and the
greatly increased concentration of C5-carnitine in the
culture medium of the lymphocytes (0.31 to 1.3 μmol/g
protein; < 0.01 in healthy controls, [1]) confirmed the
diagnosis of IVA for all patients. The biochemically
severe phenotype was also reflected by the high urinary
IVG excretion, ranging from 685 to 2.101 mmol/mol
creatinine (median: 1.256 mmol/mol creatinine; < 10 in
healthy controls) in patients not receiving glycine sup-
plementation (n = 10, Table 1).
Age at diagnosis
Twelve patients (12/21, 57%) were diagnosed within the
first 5 weeks of life, the majority of whom within the
first week (9/12, 75%) (Table 1). Symptoms ranged from
poor feeding and emesis to severe acidosis accompanied
by neurological signs and apathy. In one patient, the
initial attack of severe metabolic acidosis was lethal. In
the remaining nine patients (9/21, 43%), the diagnosis
w a sm a d ea f t e rt h ef i r s ty e a ro fl i f ed u et oa na c u t e
attack in all but two who had diagnostic work-up for
developmental delay. However, nearly all of the late
diagnosed patients in whom information was available
(7/8; 88%) also had experienced episodic symptoms dur-
ing the neonatal period including vomiting and feeding
difficulties requiring treatment.
Catabolic episodes
Overall, 69 documented moderate and severe catabolic
episodes were reported for the 21 study patients (Table
1), 41 (59%) thereof occurred in 13 study patients after
the diagnosis of IVA was made and therapy was
initiated. In most patients, the frequency of catabolic
episodes was highest during early infancy, with approxi-
mately one-fifth occurrence in the neonatal period (Fig-
ure 2), and decreased with age. No apparent catabolic
episode was observed after 9 years of age. Most com-
mon signs during episodes were recurrent vomiting and
somnolence (Figure 3). Gastroenteritis was the most
common trigger, while protein excess or surgery did not
play a major role as precipitating factors (Figure 2). In
approximately one-fifth of catabolic episodes, no trigger
was apparent.
Clinical outcome
For a total of six study patients, a concomitant disorder
was specified in the medical records/questionnaires.
One patient each suffered from bilateral cochlear deaf-
ness, hypothyroidism, a small ventricular septum defect,
and pancreatitis. Two patients had undergone pylorot-
omy in infancy due to a diagnosis of hypertrophic pylo-
ric stenosis. The physical examination was normal in
the 16 patients examined during step II of the study;
specifically, no clinical signs of organ involvement were
observed. In all patients, growth was within normal
Invitation for step II (n=20) 
 
Patients with symptomatic IVA 
n=21 
Physical and neurological examination (n=16)                          
IQ testing  (n=13)                                                         
Laboratory investigations (n=16)  
Step II (n=16) 
Review of medical records                           
Questionnaire study (attending metabolic specialists) 
Step I  (n=21) 
1 patient died  
aged 13 days 
Figure 1 Study design. Sixteen of a total of 21 study patients with
symptomatic isovaleric acidemia (IVA) were evaluated not only by
use of a questionnaire and/or medical records (step I) but also by
cross-sectional clinical, biochemical, and neurocognitive assessments
(step II). IQ = intelligence quotient.
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acidemia.
ID Age at evaluation (y) Psychomotor development
b IQ score IQ testing tool
d
1 2.2 Normal NA DDST
2 3.8 Mild retardation NA DDST
3 5.3 Normal 108 K-ABC
4 6.1 Normal 106 K-ABC
5 6.5 Normal 116 K-ABC
6 7.1 Normal 108 Kramer
7 7.5 Normal 99 K-ABC
8 8.4 Learning disability 90 K-ABC
9 10.7 Learning disability 99 K-ABC
10 10.9 Mild retardation 67 K-ABC
11
a 11.5 Normal NA NA
12 11.6 Normal 118 K-ABC
13 14.2 Learning disability 85 HAWIK-III
14 15.4 Normal 116 HAWIE-R
15
a 16.5 Learning disability 93/94
c, tested at age 8.5 y CPM/CMMS
16 19 Normal 119 HAWIE-R
17
a 20 Normal 101/91
c, tested at age 11.6 y SON/SPM
18
a 20 Normal, speech retardation at age 3.7 y NA NA
19 24.4 Normal 122 HAWIE-R
20 25.3 Severe retardation 51/45
c, tested at age 6.8 y HAWIK/Kramer
Information is provided for a total number of 20 patients (one death at 13 days of life).
ID = identification number, IQ = intelligence quotient, NA = not available, y = years
a Patient not participating in study step II.
b According to medical records/questionnaire and, in case of participation in study step II, clinical investigation.
c IQ testing not performed at study step II; information on IQ available from medical records/questionnaire only.
d CMMS = Columbia Mental Maturity Scale (Mean ± SD: 100 ± 16), CPM = Raven’s Coloured Progressive Matrices (Mean ± SD: 100 ± 15), DDST = Denver
Developmental Screening test, HAWIE-R = Wechsler Adult Intelligence Scale-Revised (Mean ± SD: 100 ± 15), HAWIK = Wechsler Intelligence Scale for Children
(Mean ± SD: 100 ± 15), HAWIK-III = Wechsler Intelligence Scale for Children Version III (Mean ± SD: 100 ± 15), K-ABC = Kaufman Assessment Battery for Children
(Mean ± SD: 100 ± 15), Kramer = Kramer IQ test (Mean ± SD: 100 ± 15), NA = not available, SPM = Raven’s Standard Progressive Matrices (Mean ± SD: 100 ± 15),
SON = Snijders-Oomen Nichtverbaler Intelligenztest-R 5
1/2-17 (Mean ± SD: 114 ± 14).
Figure 2 Triggering factors of catabolic episodes in symptomatic isovaleric acidemia (IVA). Moderate and severe catabolic episodes (n =
69) in 21 study patients with symptomatic IVA were analyzed as documented in the medical records and/or questionnaires. No specific focus of
infection was evident in febrile illnesses.
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entirely normal, whereas seven patients showed signs of
mild dyscoordination or mild motor dysfunction.
Laboratory findings (Additional file 2, Table S2) were
indicative neither of specific organ involvement nor rele-
vant nutritional deficiencies.
Psychomotor development and neurocognitive outcome
Data on psychomotor development as obtained for 20
patients from the medical records and questionnaires
(step I of the study) were predominantly normal. In two
patients mild and in one severe psychomotor retardation
was noted (Table 2, patient IDs 2, 10, 20). An early
speech development disorder was recorded in one
patient (ID 18).
The cognitive performance in terms of IQ was
obtained in 13 of the 16 step II participants aged 5 to
24 years, whereas younger children were evaluated using
DDST (Table 2). Besides cognitive impairment in the
three retarded patients mentioned above (3/16, 19%), we
identified one patient with a known diagnosis of a learn-
ing disability to be in the low-normal IQ range
(HAWIK-III 85). However, two other step II participants
with learning disabilities were tested normal, close to
the average IQ (Table 2).
Analyzing the impact of the time at diagnosis and the
number of catabolic episodes on the IQ, it turned out
that the IQ of the 13 step II participants was not related
to the number of documented moderate/severe catabolic
episodes (r = 0.12, beta = -2.15 [-5.67, 1.38], p =0 . 2 6 ) .
However, there was a significant inverse relationship
between the IQ score and age at diagnosis (in days) in
patients with not more than one severe catabolic epi-
sode (r = -0.63, beta = -0.008 [-0.001, -0.015], p < 0.05,
n = 11).
When subgrouped according to age at diagnosis, nor-
mal cognitive abilities (IQ scores) including academic
performance (absence of a learning disability) were evi-
dent in 82% (9/11) of the early diagnosed study patients
compared to only 44% (4/9) of late diagnosed study
patients (Figure 4). Furthermore, learning disabilities
were reported in three of nine (33%) late diagnosed
study patients (IDs 8, 13, 15), while only one was
affected in the early diagnosis group (9%; 1/11, ID 9)
A 
B 
C 
General signs 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Recurrent emesis
Reduced turgor
Odor of sweaty feet
Feeding difficulties
Diarrhea
Hyperventilation
Hypothermia
Neurologic signs 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Somnolence
Muscular hypotonia
Lethargy/apathy
Neurological abnormalities *
Seizures
Stupor
Coma
Sopor
Muscular hypertonia
Fantazising
Laboratory 
findings 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Ketonuria
Acidosis
Leukopenia
Hyperammonemia
Thrombocytopenia
Anemia
Neutropenia
Hyperglycemia
Hypokalemia
Hypoglycemia
Hypocalcemia
Hyperlactic acidemia
Figure 3 Clinical signs and laboratory findings at catabolic
episodes in symptomatic isovaleric acidemia (IVA). Prevalence
of clinical signs and laboratory findings during moderate and severe
catabolic episodes (n = 69) of 21 study patients with symptomatic
IVA were analyzed as documented in the medical records and/or
questionnaires. A) General clinical signs; B) neurological findings; C)
clinical chemical and hematologic abnormalities measured in blood
and urine at the time of episodes. * Neurologic abnormalities
included hyperexcitability, dyscoordination, decreased tendon
reflexes.
82%  85% 
44%  45% 
100% 
50% 
0% 
Early diagnosis  Late diagnosis 
Study patients 
Patients reported
in literature 
Figure 4 Proportion of patients with an unremarkable
neurocognitive outcome in symptomatic isovaleric acidemia.
The percentage of patients with normal cognitive abilities
(intelligence quotient [IQ] scores) including academic performance
(absence of learning disabilities) is presented for the group of study
patients (n = 20). In the group of patients reported in the literature
(n = 108), neurocognitive outcome was defined as normal if
reported as “normal” or “excellent” and/or normal IQ scores were
available. Patients were subdivided into an early diagnosis group
(defined as a diagnosis made within the first 5 weeks of life) and a
late diagnosis group (defined as a diagnosis made thereafter). Of 20
study patients, 11 were diagnosed early and nine were diagnosed
late (median 3.7 years; range 1.6-6.5 years). Of 108 patients in whom
information on neurocognitive outcome was available in the
literature, 46 were diagnosed early and 62 were diagnosed late.
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mentally retarded was diagnosed late at the age of 6.5
years (ID 20).
Patients of the literature review
Data from 155 patients with IVA were extracted from
the international literature (Additional file 1, Table S1).
Eighty-one patients were diagnosed early within the first
5 weeks of life, whereas 74 patients were diagnosed late,
seven within the first year and most of the remainder
between 1 and 6 years of age.
Mortality
Mortality in the early diagnosis group was 33% during
the initial episode of severe metabolic acidosis (Figure 5;
Additional file 1, Table S1). In the early diagnosis group,
the mean age at onset of symptoms as reported for 55
of 81 cases, was 6.8 ± 5.4 days (mean ± SD; median 6
days). Amongst them, 20 patients who died during the
initial catabolic episode had a significantly earlier onset
of symptoms (mean ± SD: 4.6 ± 2.9 days; median 3.5
days) than 35 patients who survived this initial catabolic
episode (mean ± SD: 8.1 ± 6.1 days; median 7 days) (p <
0.05). In patients diagnosed late, the mortality rate was
only 3% (Figure 5).
Neurocognitive outcome
Data on the neurocognitive outcome were reported for
108 patients (Additional file 1, Table S1). Of patients
with an early diagnosis and treatment, 85% (39/46) had
a normal cognitive outcome, whereas only 45% (28/62)
of patients with a late diagnosis had a normal cognitive
outcome (Figure 4).
Discussion
A l t h o u g hI V Ai sk n o w nf o ran u m b e ro fd e c a d e sa sa
potentially life-threatening metabolic disease and
included in NBS programs, information has remained
sparse as to the clinical course and outcome. This large
set of outcome data in patients with symptomatic IVA
provides a basis to fill this gap. The main findings are
t h a t1 )t h em o r t a l i t yr a t ei sh i g hi na s s o c i a t i o nw i t h
early neonatal presentation; 2) the neurocognitive out-
come in surviving patients with neonatal manifestation
and early start of treatment is more favourable than in
p a t i e n t sw i t hal a t ed i a g n o s i s ;a n d3 )a g ea td i a g n o s i s
but not the number of catabolic episodes has an impact
on the neurocognitive outcome.
Mortality associated with neonatal manifestation is high
but survivors benefit from early diagnosis and treatment
Analyzing the course of 155 cases with clinically evident
IVA published over a period of more than 40 years, we
found that the mortality in neonates during their initial
catabolic episode was high, with 30% much higher than
during catabolic episodes in patients who were diagnosed
later during infancy or childhood. In patients presenting
acutely in the neonatal period, the mean age at onset of
the first potentially life-threatening catabolic episode was
6.8 days and was even earlier (4.6 days) in patients who
died during the initial catabolic episode. A way out of this
high mortality rate in the past can be expected through
the addition of IVA as a target disease to NBS programs,
which recently took place in a number of countries. At
least in the German and various European NBS programs,
blood sampling of the newborn is to be performed
between 36 and 72 hours of life, and the communication
of a positive screening result can thus be expected to take
place between day 4 and 7 of life. Hence, for many patients
with an acute neonatal manifestation of IVA, the NBS
result arrives in time to prevent severe clinical manifesta-
tion and exert the proper treatment, thus bearing the
potential of reducing early mortality.
Looking at the psychomotor development and neuro-
cognitive outcome in later life, study patients who sur-
vived an acute neonatal manifestation appear to benefit
from early diagnosis and start of therapeutic measures
including a protein-restricted diet and carnitine/glycine
supplementation. These patients showed later a better
neurocognitive outcome than patients who were not
diagnosed before childhood. This was in accordance
with the results of our literature review based on a large
series of patients with IVA (Figure 4).
When the overall neurocognitive outcome of the dis-
order is considered, it appears less devastating compared
to other “classical” organic acidemias/acidurias such as
methylmalonic aciduria (MMA) and propionic acidemia
(PA) [7,8]. In our own IVA study population,
100% 
50% 
0% 
Alive 
Deceased
Early diagnosis  Late diagnosis 
67% 
33% 
97% 
3% 
Figure 5 Survival data of 155 patients with symptomatic
isovaleric acidemia reported in the literature. Early diagnosis
was defined as a diagnosis made within the first 5 weeks of life (n
= 81), late diagnosis was defined as a diagnosis made thereafter (n
= 74).
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than 80% of patients (13/16) as assessed by developmen-
tal/IQ testing. However, despite normal IQ outcome,
minor disabilities including reported learning disability
and earlier speech retardation were evident in a signifi-
cant proportion (25%) of the study patients (5/20).
Exclusion of these cases led to a percentage of 60% of
patients (12/20) with an entirely normal neurocognitive
outcome/psychomotor development and unremarkable
academic performance. This is in agreement with data
obtained from our literature review: 62% (67/108) of
patients with IVA, either diagnosed early or late, were
reported to have a normal neurocognitive outcome
while the remainder of patients was impaired (Addi-
tional file 1, Table S1). Severe mental retardation was
reported in only six (4%) of 155 patients, similar to our
study population (5%).
No significant long-term complications beyond the
central nervous system (CNS) involvement - mild motor
dysfunction and cognitive deficits - were evident in our
study patient population. The majority of patients
showed a normal physical development. Similar observa-
tions have been reported by Martin-Hernandez et al [9]
who studied four adult IVA patients. All of them had
normal growth and none showed visceral complications.
Thus, in contrast to MMA or PA in which long-term
complications like failure to thrive [10], renal failure [7],
or cardiac complications [11] are common, IVA does
not seem to be a multisystemic disorder. Besides its
beneficial neurocognitive outcome, the high potential of
a normal physical development without restrictive long-
term complications in affected patients additionally
emphasizes the value of early, pre-symptomatic diagno-
sis by means of NBS.
The neurocognitive outcome is not related to the number
of catabolic episodes
Among several factors suggested to influence the long-
term outcome of patients with IVA including genotype
[1], residual IVD activity, and quality of therapy, the
number and severity of catabolic episodes might deter-
mine the neurocognitive outcome. However, in the pre-
sent study no significant relationship between the
number of moderate and severe catabolic episodes the
patients had experienced and their IQ at study was
found. Some patients had normal IQs despite severe
c a t a b o l i ce p i s o d e sw i t hc o m aw h i l eo t h e r sw i t ha n
apparently milder clinical course showed cognitive
impairment. Similar observations have been made in
patients reported in the literature [9,12-14].
The underlying pathophysiologic mechanisms leading
to cerebral damage are still not fully elucidated. Based on
studies in rats it can be presumed that metabolites accu-
mulating in IVA induce oxidative stress in the brain
cortex and that oxidative damage may be at least in part
involved in the neuropathology of IVA [15]. Additionally,
it was recently shown that particularly free isovaleric acid
reduces Na+, K+-ATPase activity in synaptic membranes
from cerebral cortex of young rats, possibly via mechan-
isms involving lipid peroxidation [16]. It might be
hypothesized that every severe catabolic episode causes
cerebral damage to some extent by means of the accumu-
lating free isovaleric acid. However, considering the lack
of association between the number of catabolic episodes
and cognitive performance (IQ) and the finding that early
diagnosis and treatment have a positive impact on the
neurocognitive outcome, chronic rather than acute
damage might be the predominant factor determining
the extent of neuropathology in patients with IVA. A
possible explanation might be that in patients on treat-
ment, most of the persistently accumulating and poten-
tially neurotoxic free isovaleric acid is converted into
non-toxic carnitine and glycine conjugates. This implies
that patients with the later manifesting form of IVA will
also benefit from early diagnosis by NBS.
Nevertheless, patients with a clinically relevant form of
IVA are constantly at risk of severe, potentially life-
threatening acidotic decompensations during catabolic
stress. As in other “classical” organic acidemias/acidurias
the frequency of metabolic attacks is highest during
early infancy and subsequently decreases with age [17].
In our patient population no catabolic episodes were
observed after the age of 9 years. This is in accordance
with a recent report of four adult IVA patients by Mar-
tin-Hernandez et al [9], who also have remained meta-
bolically stable since adolescence. This might be partly
explained by the reduced number of infections, a rele-
vant triggering factor as shown here, with age [17].
Additionally, it has been discussed that alternative meta-
bolic pathways leading to detoxification of accumulating
metabolites in IVA can be better utilized with age [18].
However, sparse informationo na d o l e s c e n ta n da d u l t
patients in the literature indicates that even patients
who have been metabolically stable for more than one
decade are still prone to metabolic decompensation in
episodes of catabolic stress [19-21]. Towards adoles-
cence and adulthood, trigger factors may change and
comprise general anesthesia, excessive sports and physi-
cal exertion, low-calorie diets and fasting, pregnancy,
and alcohol potentially resulting in a catabolic state with
increased endogenous protein turnover and the risk of
potentially life-threatening crises. Thus, besides conti-
nuation of treatment, awareness of the disease risks is a
life-long essential in patients with symptomatic IVA.
Conclusion
Within the entity of “classical” organic acidurias which
typically result in significant CNS damage, IVA appears
Grünert et al. Orphanet Journal of Rare Diseases 2012, 7:9
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implications, possibly entirely preventable by treatment.
The potential to avoid early mortality and to improve
neurocognitive outcome by early diagnosis and treat-
ment encourages pre-symptomatic diagnosis and rein-
forces IVA to be qualified for NBS.
Additional material
Additional file 1: Table S1: Literature review of 155 reported
patients with symptomatic isovaleric acidemia; Supplementary
References.
Additional file 2: Table S2: Clinical chemical and biochemical
parameters analyzed in step II participants with symptomatic
isovaleric acidemia.
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